NEW YORK (GenomeWeb News) — Lipomics Technologies will use certain Agilent Technologies products under a research and diagnostic assay-development agreement, Lipomics said today.
Lipomics said it plans to develop biomarker-based assays focused on metabolic diseases caused by problems with lipid regulation.
Terms of the deal call for Agilent to contribute its 2100 Bioanalyzer and other products, including liquid and gas chromatographers, microarrays, and software as they are required, Lipomics said.
Lipomics said it measures more than 1,500 metabolites to generate profiles of lipid metabolism throughout the body.
Michael McNulty, general manager of Agilent’s diagnostics, life sciences, and chemical analysis business, said “both companies see significant synergies in combining” Lipomics’ experience with lipids and disease with Agilent’s “capabilities to separate, detect and analyze molecules. … ”
Financial terms of the agreement were not released.